Femasys (FEMY) Income from Continuing Operations (2020 - 2025)
Femasys (FEMY) posted Income from Continuing Operations of 4585922.0 for Q2 2025, up 22.23% on a QoQ basis from 5896839.0 in Q1 2025, and up 2.11% year-over-year from 4491339.31 in Q2 2024.
Femasys (FEMY) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Femasys' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 4585922.0 for Q2 2025.
- Quarterly Income from Continuing Operations rose 2.11% year-over-year to 4585922.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 21015305.0 (down 25.9% YoY) and the FY2025 annual result came in at 18627615.0, up 1.0% from the prior year.
- Income from Continuing Operations was 4585922.0 for Q2 2025 at Femasys, up from 5896839.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1083059.0 in Q2 2021 and bottomed at 5896839.0 in Q1 2025.
- A 5-year average of 3499165.78 and a median of 3052943.5 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations increased 27.09% — and 2022, when it plunged 162.38%.
- Femasys' Income from Continuing Operations stood at 2364853.0 in 2021, then slipped by 27.44% to 3013804.0 in 2022, then plunged by 46.34% to 4410454.0 in 2023, then fell by 16.17% to 5123684.0 in 2024, then rose by 10.5% to 4585922.0 in 2025.
- Business Quant data shows FEMY's Income from Continuing Operations at 4585922.0 in Q2 2025, 5896839.0 in Q1 2025, and 5123684.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 33,163,703.85 Bn | 33,163,702.19 Bn | 1.53 Bn | 240.00 Mn |
| 2 | Intuitive Surgical | 119.67 Bn | 114.45 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Becton Dickinson | 43.92 Bn | 43.11 Bn | 2.15 Bn | -37.00 Mn |
| 4 | Medline | 31.71 Bn | 29.47 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 28.46 Bn | 26.80 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.80 Bn | 23.28 Bn | 296.40 Mn | 135.40 Mn |
| 7 | Cooper Companies | 13.77 Bn | 13.63 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Solventum | 13.63 Bn | 13.06 Bn | 1.10 Bn | 13.00 Mn |
| 9 | Align Technology | 11.94 Bn | 10.88 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Femasys | 17.09 Mn | 11.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -3.04 Mn |
| Dec 31, 2022 | -3.01 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -2.89 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.57 Mn |